Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

EBR:BTLS - Euronext Brussels - BE0974386188 - Common Stock - Currency: EUR

3.67  -0.02 (-0.54%)

Fundamental Rating

2

Taking everything into account, BTLS scores 2 out of 10 in our fundamental rating. BTLS was compared to 66 industry peers in the Chemicals industry. The financial health of BTLS is average, but there are quite some concerns on its profitability. BTLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTLS has reported negative net income.
In the past year BTLS has reported a negative cash flow from operations.
In the past 5 years BTLS always reported negative net income.
In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

BTLS has a Return On Assets of -69.57%. This is amonst the worse of the industry: BTLS underperforms 93.94% of its industry peers.
Looking at the Return On Equity, with a value of -104.77%, BTLS is doing worse than 89.39% of the companies in the same industry.
Industry RankSector Rank
ROA -69.57%
ROE -104.77%
ROIC N/A
ROA(3y)-42.02%
ROA(5y)-36.72%
ROE(3y)-56.2%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

BTLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, BTLS has more shares outstanding
The debt/assets ratio for BTLS is higher compared to a year ago.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

BTLS has an Altman-Z score of 6.56. This indicates that BTLS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.56, BTLS belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that BTLS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.23, BTLS is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 6.56
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

BTLS has a Current Ratio of 3.88. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.88, BTLS belongs to the top of the industry, outperforming 92.42% of the companies in the same industry.
A Quick Ratio of 3.88 indicates that BTLS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.88, BTLS belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

BTLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.74%, which is quite good.
EPS 1Y (TTM)11.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BTLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -43.83% yearly.
Based on estimates for the next years, BTLS will show a very strong growth in Revenue. The Revenue will grow by 56.92% on average per year.
EPS Next Y0%
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%
EPS Next 5Y-43.83%
Revenue Next Year233.33%
Revenue Next 2Y15.47%
Revenue Next 3Y18.56%
Revenue Next 5Y56.92%

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M 8M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTLS. In the last year negative earnings were reported.
Also next year BTLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

BTLS's earnings are expected to decrease with -28.96% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (5/30/2025, 7:00:00 PM)

3.67

-0.02 (-0.54%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners23.43%
Inst Owner ChangeN/A
Ins Owners4.85%
Ins Owner ChangeN/A
Market Cap137.51M
Analysts87.5
Price Target6.58 (79.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.02
P/tB 7.25
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.52
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.57%
ROE -104.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.02%
ROA(5y)-36.72%
ROE(3y)-56.2%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z 6.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.61%
Cap/Depr(5y)129.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.2%
EPS Next Y0%
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%
EPS Next 5Y-43.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year233.33%
Revenue Next 2Y15.47%
Revenue Next 3Y18.56%
Revenue Next 5Y56.92%
EBIT growth 1Y7.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.48%
EBIT Next 3Y4.4%
EBIT Next 5Y-24.57%
FCF growth 1Y15.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.09%
OCF growth 3YN/A
OCF growth 5YN/A